Evidence map›Paper›PMID 25602249›Full record

ReviewCurrent opinion in psychiatry2015

An update on anxiety in youth with autism spectrum disorders.

Roma A Vasa, Micah O Mazurek

Registry-linked trialAbstract readReview
In one paragraph

Review in Current opinion in psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03279471 (Specifying and Treating the Anxiety Phenotype in Autism Spectrum Disorder), which is not on this map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03279471 phase2completednot on this mapstarted 2017, after this paper: background citation

Specifying and Treating the Anxiety Phenotype in Autism Spectrum Disorder

TypeinterventionalSponsorUniversity of California, DavisRan2017 to 2023Enrolled68ConditionsAutism Spectrum Disorder, AnxietyArmsSertraline, CBT/BIACA, Placebo
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Memantine for autism spectrum disorder.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Pooled it
  3. How well can commonly used anxiety scales detect treatment outcomes in the context of autism?Autism : the international journal of research and practice · 2025
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Roma A VasaaKennedy Krieger Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland bDepartment of Health Psychology, Thompson Center for Autism and Neurodevelopmental Disorders, University of Missouri, Columba, Missouri, USA.
Micah O Mazurek
Center for Autism and Related Disorders · US

Funding

STEPS: Stepped Transition in Education Program for Students with ASDR34MH104337 · NIMH · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI WHITE, SUSAN WILLIAMS · 2014 to 2016
$666k
Development of a novel neurotechnology to promote emotion recognition in autismR21MH100268 · NIMH · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI WHITE, SUSAN WILLIAMS · 2014 to 2015
$495k
Developing an Automated Emotion Training SystemR03HD081070 · NICHD · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI ABBOTT, AMOS LYNN, WHITE, SUSAN WILLIAMS · 2015 to 2016
$147k
NICHD NIH HHS R03 HD081070NIMH NIH HHS R21 MH100268NIMH NIH HHS R34 MH104337
6 · The paper itself

Abstract

purpose of reviewAnxiety is one of the most common co-occurring psychiatric conditions in youth with autism spectrum disorders (ASDs). This article reviews recent evidence as well as earlier relevant studies regarding the characteristics, assessment, and treatment of anxiety in youth with ASD. RECENT

findingsIt is well established that the prevalence of anxiety in youth with an ASD is significantly greater than the prevalence of anxiety in the general population. Recent studies have highlighted the importance of informant, method, and instrument when measuring anxiety in this population. Despite the high prevalence, findings to date have been unable to identify any consistent risk factors for anxiety. New psychological treatments, including modified cognitive behavioral therapy for youth with high functioning ASD and co-occurring anxiety, are emerging. Pharmacological data, however, are scant. Existing studies show that youth with ASD are at increased risk for behavioral activation when taking SSRIs. SUMMARY: Clinicians working with youth with ASD are encouraged to routinely screen for anxiety. Until further data are available, clinical judgment is needed when prescribing treatments, particularly selective serotonin reuptake inhibitors, which require close monitoring of side-effects. Research on risk factors, pathophysiology, and treatment of this condition is needed.

Indexed as

AdolescentAnxietyChildChild Development Disorders, PervasiveHumans

Identifiers

PMID25602249
PMCPMC5764108
OpenAlexW2021041873

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.